Affiliation:
1. Medical adviser, Pharma Nord (UK) Ltd
Abstract
Mitochondrial dysfunction, oxidative stress and inflammation have been implicated in the pathogenesis of multiple sclerosis (MS). Therefore, there is a rationale for the use of supplementary coenzyme Q10 (CoQ10) as a potential novel therapeutic agent for this disorder, based on the key roles of this vitamin-like substance in normal mitochondrial function, as an antioxidant and as an anti-inflammatory agent. In this article, the pre-clinical and clinical studies relating to the use of supplementary CoQ10 for the treatment of MS is reviewed.
Subject
Neurology (clinical),General Nursing